Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PT-112 + Avelumab in Advanced Solid Tumors
NCT03409458Phase 2Completed
- Sponsor
- Promontory Therapeutics
- Start
- Apr 2018
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of Imifoplatin in solid tumor (advanced stage), non-small cell lung cancer (NSCLC) and metastatic castration-resistant prostate cancer (mCRPC), sponsored by Promontory Therapeutics. Primary endpoint: Best Overall Response Rate at 24 months. Started Apr 2018; status: completed.
02
Drugs
Imifoplatin
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03409458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03409458.